Compare Abeona Therapeutics Inc (ABEO) vs Nike Inc (NKE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Nike Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Nike Inc trades at $43.1 (market cap $63.99B). The key difference: Nike Inc is far larger — about 171.4× Abeona Therapeutics Inc's market cap, and Nike Inc pays a 3.8% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | NKE | |
|---|---|---|
Market Cap | $373.32M | $63.99B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $79.24 |
52-Week Low | $4.17 | $40.75 |
Enterprise Value | $228.22M | $66.00B |
Volume | — | 8,887,180 |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Nike (NKE) trades at $43.34, down 1.7% on the day, with a bearish technical signal and mixed sentiment. Recent earnings have consistently beaten estimates, but revenue declined to $46.31B in 2025 with net income falling to $3.22B. The stock shows strong profitability margins and a P/E of 20.64, while analysts maintain a consensus Buy rating with a $50.67 price target. Key support lies at $42, with resistance at $44.
Nike faces near-term headwinds from sluggish consumer demand and margin pressure, but its brand strength and digital direct-to-consumer strategy provide long-term upside potential. Risks include inventory challenges and economic sensitivity, yet institutional confidence remains with 48.6% analyst Buy ratings. The upcoming Q4 2026 earnings on June 30, 2026, will be critical for confirming turnaround progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
